NASDAQ:KYTH

(KYTH) (KYTH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.09
$0.09
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KYTH stock logo

About (KYTH) Stock (NASDAQ:KYTH)

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

KYTH Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Agro Capital Management Corp ACMB
Xponential Fitness to acquire Lindora
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
RCI Hospitality declares $0.06 dividend
eXp World Holdings Inc 44Y
PBA draft a rich harvest
Animals dream too—here's what we know
See More Headlines
Receive KYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KYTH) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2015
Today
4/24/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KYTH
CUSIP
50157010
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

KYTH Stock Analysis - Frequently Asked Questions

How were (KYTH)'s earnings last quarter?

(KYTH) (NASDAQ:KYTH) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter.

What other stocks do shareholders of (KYTH) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (KYTH) investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), (RPTP) (RPTP), Altaba (AABA), Intercept Pharmaceuticals (ICPT), Incyte (INCY), NPS Pharmaceuticals (NPSP), OPKO Health (OPK) and Puma Biotechnology (PBYI).

This page (NASDAQ:KYTH) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners